Update on proposal to fund ferric carboxymaltose infusions in the community
PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal to list ferric carboxymaltose (Ferinject) 500 mg per 10 ml vial in Section B of the Pharmaceutical Schedule from 1 August 2017 for the treatment of iron deficiency anaemia.
Consultation on this proposal has now closed. We received a large number of detailed responses during consultation from a wide range of interested parties which we are taking more time to carefully consider. This means a decision on the proposal will be delayed and the proposed listing will not occur on 1 August 2017.
PHARMAC expect a decision to be made, and subsequently notified, on this proposal in the future.
We’d like to thank everyone who took the time to provide feedback.
If you have any questions about this notification, please email PHARMAC at email@example.com.